Yes, primidone causes drowsiness, particularly severe drowsiness when first starting the medication.
Primidone commonly causes drowsiness and sedation, especially after initial doses, and this is explicitly warned about in the FDA labeling. 1 The FDA-approved prescribing information specifically states that "primidone tablets can make you sleepy or dizzy" and warns that "sleepiness can be severe, especially when you first start taking primidone." 1
Severity and Timing of Drowsiness
The drowsiness associated with primidone follows a characteristic pattern:
- Acute onset: Sedation is most severe after the first dose, with up to 82% of patients experiencing acute neurotoxic symptoms including somnolence when starting primidone without phenobarbital pre-treatment 2
- Early treatment phase: Drowsiness remains common at 4 weeks and 3 months of treatment 3
- Gradual improvement: Sedative effects tend to subside over time with continued use 3
Clinical Impact
The drowsiness from primidone can be clinically significant enough to:
- Impair driving ability: The FDA label explicitly warns not to drive or operate heavy machinery until you know how primidone affects you 1
- Slow thinking and motor skills: Primidone can impair cognitive and psychomotor function 1
- Lead to treatment discontinuation: In one study, 3 of 11 patients (27%) discontinued primidone because sedative effects outweighed therapeutic benefits 3
Important Caveats
Avoid alcohol and other CNS depressants: Taking primidone with alcohol or other sedating medications can worsen drowsiness and dizziness 1. Multiple guidelines warn about additive sedative effects when combining primidone with other CNS-active drugs 4, 5.
Elderly patients are particularly vulnerable: Older patients are more prone to sedation and cognitive effects from primidone 4. This is especially relevant since essential tremor (a common indication for primidone) predominantly affects older adults.
Mitigation Strategy
Phenobarbital pre-treatment can minimize acute drowsiness: Starting with low-dose phenobarbital (10 mg/day for 2-3 weeks) before initiating primidone reduces the prevalence of acute neurotoxic symptoms from 82% to 17% through functional cross-tolerance 2. This approach should be considered for patients in whom primidone therapy is indicated, particularly those who previously could not tolerate the medication.
Gradual dose titration is essential: Starting with very low doses (31.5-62.5 mg) and slowly increasing helps improve tolerability 6, 7. The drowsiness reported by patients often disappears or diminishes significantly by the end of the titration period 6.